Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 1703 • ACR Convergence 2022
Potential Regulation of NK Cells by CD1c+ Dendritic Cells Through RIG-I/DDX60 Pathway Involved in Th17 Responses in Primary Sjögren Syndrome
Ildefonso Sánchez Cerrillo¹, Marta Calvet Mirabent¹, Ana Triguero², Diego Calzada Fraile³, Mariel Valdivia¹, Marta Ramírez³, Enrique Vázquez de Luis³, Alberto Benguría Filippini³, Roberto Moreno³, María Magdalena Adrados de llano¹, Hortensia de la Fuente¹, Ilya Tsukalov⁴, Emilia Roy Vallejo⁵, Almudena Ramiro³, Salvador Iborra⁶, Francisco Sánchez Madrid¹, Ana Dopazo³, Isidoro Gonzalez⁷, Santos Castañeda⁸ and Enrique Martín Gayo⁴, ¹Hospital La Princesa, Madrid, Spain, ²Hospital Universitario La Princesa, Madrid, Spain, ³Centro de Investigaciones Cardiovasculares, Madrid, Spain, ⁴Universidad Autónoma de Madrid, Madrid, Spain, ⁵Internal Medicine Department, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain, ⁶Universidad Complutense de Madrid, Madrid, Spain, ⁷Hospital Universitario de La Princesa, Madrid, Spain, ⁸Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain
Background/Purpose: Altered Th17, CD8+ T cell and B cell adaptative immune responses in patients with primary Sjögren syndrome (pSS) have been characterized in salivary glands…
Abstract Number: 2030 • ACR Convergence 2022
Designing of a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Inhibitor, in Adults with Primary Sjögren’s Syndrome
Jonathan Hubbard¹, Kim Campbell¹, Kathy Sivils¹, Robert Hoffman¹, Kim Hung Lo¹, Jocelyn Leu¹, Sophia Liva¹, Qing Zuraw¹, Anne Stevens¹, Leona Ling², Keith Karcher³, Sindhu Ramchandren³, Hong Sun³, Hal Scofield⁴, Daniel Wallace⁵ and Raphaèle Seror⁶, ¹Janssen Research and Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, Cambridge, MA, ³Janssen Research & Development, LLC, Titusville, NJ, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶University Hospital Paris-Saclay, Le Kremlin Bicêtre, France
Background/Purpose: Dysregulated humoral immunity is a hallmark of primary Sjögren's Syndrome (pSS). This dysregulation involves aberrant B-lymphocyte activity resulting in abnormally high immunoglobulin G (IgG)…
Abstract Number: 2046 • ACR Convergence 2022
Agreement Between Labial Biopsy and the OMERACT Grey-scale Ultrasound Scoring System for Salivary Glands in a Single-center Cohort of Patients with Suspected Sjögren’s Syndrome
Viktoria Fana¹, Nanna Surlemont Schmidt², Uffe Møller Døhn¹, Simon Krabbe³ and Lene Terslev⁴, ¹Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ²Rigshospitalet, Copenhagen, Denmark, ³Rigshospitalet, København, Denmark, ⁴Copenhagen University Hospital Glostrup, Glostrup, Denmark
Background/Purpose: Ultrasound is a promising non-invasive tool in the evaluation of the salivary glands for parenchymal changes related to Sjögrens Syndrome (SS). The OMERACT Ultrasound…
Abstract Number: 0814 • ACR Convergence 2022
Clinical Correlation of Dense Fine Speckled (DFS) Pattern of ANA
Smarika Sapkota¹, Jerry Molitor², michael evans², Benjamin Kofoed³, Adam Lord³, Londyn Robinson³ and John crosson², ¹University of Colorado, Aurora, CO, ²University of Minnesota, Minneapolis, MN, ³University of Minnesota Medical School, Minneapolis, MN
Background/Purpose: The clinical significance of Dense Fine Speckled (DFS) pattern Anti-nuclear antibodies (ANA) by indirect immunofluorescence method (IIF) is unclear and has been inversely associated…
Abstract Number: 1734 • ACR Convergence 2022
Identification of Sjögren’s Disease-Associated T Cell Receptors Through Deep Sequencing and Single-Cell Transcriptomics
Ananth Aditya Jupudi¹, Michelle Joachims¹, Christina Lawrence¹, Charmaine Lopez-Davis¹, Bhuwan Khatri¹, Astrid Rasmussen¹, Lida Radfar², Kiely Grundahl¹, R. Hal Scofield², Judith James¹, Joel Guthridge¹, Christopher Lessard¹, Linda F. Thompson¹ and A. Darise Farris¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren's disease (SjD) is a chronic rheumatic autoimmune disorder that primarily targets the lacrimal and salivary glands (SG) resulting in dry eyes and dry…
Abstract Number: 2031 • ACR Convergence 2022
Efficacy and Safety of Telitacicept in Primary Sjögren’s Syndrome: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial
Dong Xu¹, Shangzhu Zhang¹, Cibo Huang², Chenghui Huang³, Li Qin⁴, Xiaomei Li⁵, Meiqing Chen⁶, Xiumei Liu⁷, Yi Liu⁸, Zhijun Li⁹, Jiankang Hu¹⁰, Chunde Bao¹¹, wei Wei¹², Jing Tian¹³, Xinwang Duan¹⁴, Jianmin Fang¹⁵ and Xiaofeng Zeng¹⁶, ¹Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Beijing Hospital, Beijing, China, ³The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, ⁴Huzhou Third Municipal Hospital, Huzhou, China, ⁵Anhui Provincial Hospital, Hefei, China, ⁶The First Affiliated Hospital of Xiamen University, Xiamen, China, ⁷The First Hospital of Shanxi Medical University, Taiyuan, China, ⁸West China Hospital of Sichuan University, Chengdu, China, ⁹The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ¹⁰Jiangxi Pingxiang People’s Hospital, Shanghai, China, ¹¹Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, ¹²Tianjin Medical University General Hospital, Tianjin, China, ¹³Second Xiangya Hospital of Central South University, Changsha, China, ¹⁴The Second Affiliated Hospital of Nanchang University, Nanchang, China, ¹⁵Shanghai Tongji Hospital, Shanghai, China, ¹⁶Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: To evaluate the efficacy and safety of telitacicept in adult patients with primary Sjögren’s syndrome (pSS) in a phase II randomized double-blind placebo-controlled trial.Methods:…
Abstract Number: 2047 • ACR Convergence 2022
Discriminative Power of Salivary Gland Ultrasound in Relation to Symptom-based Endotypes in Suspected and Definite Primary Sjögren’s Syndrome
Liselotte Deroo¹, Helena Achten², Eva Genbrugge², Wouter Bauters², Dimitri Roels², Frederick Dochy², David Creytens², Ann-Sophie Kathleen De Craemer², Filip Van den bosch³, Dirk Elewaut⁴ and isabelle peene⁵, ¹Ghent University, Gent, Belgium, ²Ghent University Hospital, Gent, Belgium, ³Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ⁴Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium, ⁵Ghent University Hospital, Ghent, Belgium
Background/Purpose: Primary Sjögren's Syndrome (pSS) is characterized by xerophthalmia, xerostomia and increased lymphoma risk. To address heterogeneity in symptoms, Tarn et al. applied cluster analysis…
Abstract Number: 0827 • ACR Convergence 2022
Unpublished Clinical Trials of Major Rheumatic Diseases
Connor Pedersen¹, Mike Putman², Erin Valley¹, Kathryn Henry³, Ali Duarte-Garcia⁴, Shikha Singla⁵ and Shannon Tai¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²The Medical College of Wisconsin, Milwaukee, WI, ³Medical College of Wisconsin, Manitowoc, WI, ⁴Mayo Clinic, Rochester, MN, ⁵MCW, Fox Point, WI
Background/Purpose: Randomized controlled trials (RCTs) provide high-quality evidence for treatment efficacy, but many RCTs remain unpublished. The objective of this study was to describe the…
Abstract Number: 1947 • ACR Convergence 2022
Medication Use in Childhood Sjogren Disease
Erin Treemarcki¹, Matthew Basiaga², Scott Lieberman³ and Sara Stern¹, ¹University of Utah, Salt Lake City, UT, ²Mayo Clinic, Inver Grove Heights, MN, ³University of Iowa, Iowa City, IA
Background/Purpose: Childhood Sjogren’s Disease (childSD) is a rare complex chronic autoimmune disease primarily affecting lacrimal and salivary glands. Currently there is a paucity of information…
Abstract Number: 2032 • ACR Convergence 2022
Major Salivary Gland Ultrasound and Elastography for Assessment of Disease Activity in Patients of Primary Sjögren’s Syndrome
Kunal Chandwar¹, Juhi Dixit¹, Kriti Kishor¹, DOGGA PRASANNA KUMAR², DIGVIJAY EKBOTE³, PUNEET KUMAR¹ and Urmila Dhakad¹, ¹King George's Medical University, Lucknow, India, ²KGMU, LUCKNOW, Uttar Pradesh, India, ³KING GEORGE MEDICAL UNIVERSITY, LUCKNOW, Uttar Pradesh, India
Background/Purpose: To assess major salivary gland involvement by ultrasonography and elastography in patients with Sjögren's syndrome , compare it with controls and correlate the severity…
Abstract Number: 2048 • ACR Convergence 2022
Serology Driven Pulmonary Phenotype Characterization of Sjögren Syndrome-associated Interstitial Lung Disease: A Monocentric Cohort Study
Gaetano La Rocca¹, Francesco Ferro², Giovanni Fulvio³, Silvia Fonzetti⁴, Inmaculada Concepción Navarro García⁵, Elena Elefante⁶, Chiara Romei⁷, Marta Mosca⁶ and Chiara Baldini³, ¹University of Pisa, Rheumatology Unit, Palermo, Palermo, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³University of Pisa, Pisa, Pisa, Italy, ⁴Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, ⁵Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁶University of Pisa, Pisa, Italy, ⁷University of Pisa, Rheumatology Unit, Pisa, Italy
Background/Purpose: Interstitial lung disease (ILD) is a relatively frequent manifestation of Sjögren's Syndrome (pSS), potentially presenting with a wide spectrum of clinical-radiological characteristics. Anti-Ro52 autoantibodies…
Abstract Number: 0957 • ACR Convergence 2022
Timeliness of Fetal Echocardiography for Congenital Heart Block Detection in Anti-Ro/La-Positive Pregnancies
Amanda Ohayon¹, Nikola Wilk¹, Arielle Mendel², Mayssa Moukarzel¹, Jessica Simoneau¹, Wadi Mawad¹, Gabriel Altit¹ and Evelyne Vinet², ¹McGill University Health Center, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Best practice guidelines recommend screening for congenital heart block (CHB) in anti-Ro/La-positive pregnancies with serial echocardiography starting between 16 to 18 weeks of gestational…
Abstract Number: 2017 • ACR Convergence 2022
Characteristics and Prognosis Factors of Relapse or Death for Non-Hodgkin Lymphomas in Primary Sjögren Syndrome
Juliette Rocca¹, Maxime Beydon², Veronique Le Guern³, Eric Hachulla⁴, Jean Jacques Dubost⁵, sandrine jousse joulin⁶, Valerie Devauchelle⁷, Jacques-Eric Gottenberg⁸, Olivier Vittecoq⁹, Christian Lavigne¹⁰, Jean Schmidt¹¹, Christian Marcelli¹², Claire Larroche¹³, Xavier Mariette¹⁴, Raphaèle Seror¹⁵ and Gaetane Nocturne¹⁶, ¹APHP, Paris, France, ²Université Paris Cité, Paris, France, ³Hôpital Cochin, Paris, France, ⁴University of Lille, LILLE, France, ⁵University Hospital of Clermont Ferrand, Rheumatology, Clermont-Ferrand, France, ⁶Roche, Brest, France, ⁷Université de Bretagne Occidentale, Brest, France, ⁸University of Strasbourg, Strasbourg, France, ⁹CHU de Rouen, ROUEN, France, ¹⁰CHU Angers, Angers, France, ¹¹CHU Amiens, Amiens, France, ¹²CHU Caen, Caen, France, ¹³APHP, Bobigny, France, ¹⁴Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹⁵University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, ¹⁶APHP, Le Kremlin Bicêtre, France
Background/Purpose: Primary Sjögren Syndrome (pSS) patients present an increased risk of Non-Hodgkin lymphoma (NHL). There is no consensus on the therapeutic management of low-grade NHL.…
Abstract Number: 2033 • ACR Convergence 2022
Novel Autoantibodies Identified in Seronegative Sjögren’s Disease Using Innovative Whole Peptidome Array Technology
Maxwell Parker, Zihao Zheng, Quinn Parker, Addie Vande Loo, Michael Newton, Miriam Shelef and Sara McCoy, University of Wisconsin, Madison, WI
Background/Purpose: SjD disease (SjD) is typically diagnosed by the presence of an anti-SSA antibody or focal lymphocytic sialadenitis in salivary gland tissue. Among SjD patients…
Abstract Number: 2049 • ACR Convergence 2022
ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive
Anna-Maria Hoffmann-Vold¹, Håvard Fretheim¹, Phoung Phoung Diep¹, Karoline Lerang², Birgir Gudbransson¹, Helena Andersson¹, Øyvind Midtvedt¹, Torhild Garen¹, Michael Durheim¹, Trond Mogens Aaløkken¹, Øyvind Palm¹ and Øyvind Molberg², ¹Oslo University Hospital, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Interstitial lung disease (ILD) in primary Sjögren's syndrome (pSS) has been reported to be present in 10-15% of patients, but ILD progression in pSS-ILD…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].